New drug duo takes on Hard-to-Treat kidney cancer
NCT ID NCT06234605
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new oral drug called HC-7366 combined with the approved drug belzutifan in about 80 adults with advanced kidney cancer that cannot be surgically removed. The main goal is to find the safest dose and check for any serious side effects. Researchers will also watch for signs that the combination can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HC-7366 (a drug that activates a protein called GCN2) combined with belzutifan (a drug that blocks HIF-2α)
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with advanced kidney cancer that has not responded to other therapies.
- What could go wrong
- This is an early Phase 1b trial with only 80 participants, so the main goal is safety and dosing—not proof of effectiveness. The combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
HealthPartners Cancer Research Center
RECRUITINGSaint Paul, Minnesota, 55101, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
-
Rocky Mountain Cancer Centers, LLP
RECRUITINGLone Tree, Colorado, 80124, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Swedish Medical Center
RECRUITINGSeattle, Washington, 98104, United States
-
Texas Oncology
RECRUITINGDallas, Texas, 75246, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
-
University Medical Center & Texas Tech Health Science Center
RECRUITINGLubbock, Texas, 79430, United States
-
University of Arizona Cancer Center
RECRUITINGTucson, Arizona, 85719, United States
-
University of California San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
-
University of Colorado Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
-
University of Wisconsin - Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
-
Yale - New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?